CA2899786C - Induced dendritic cells and uses thereof - Google Patents

Induced dendritic cells and uses thereof Download PDF

Info

Publication number
CA2899786C
CA2899786C CA2899786A CA2899786A CA2899786C CA 2899786 C CA2899786 C CA 2899786C CA 2899786 A CA2899786 A CA 2899786A CA 2899786 A CA2899786 A CA 2899786A CA 2899786 C CA2899786 C CA 2899786C
Authority
CA
Canada
Prior art keywords
cells
human
mice
smyledc
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2899786A
Other languages
English (en)
French (fr)
Other versions
CA2899786A1 (en
Inventor
Renata STRIPECKE
Gustavo SALGUERO-LOPEZ
Anusara DAENTHANASANMAK
Arnold Ganser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hannover Medical School
Original Assignee
Hannover Medical School
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hannover Medical School filed Critical Hannover Medical School
Publication of CA2899786A1 publication Critical patent/CA2899786A1/en
Application granted granted Critical
Publication of CA2899786C publication Critical patent/CA2899786C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
CA2899786A 2013-02-07 2014-01-24 Induced dendritic cells and uses thereof Active CA2899786C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2013/052485 2013-02-07
PCT/EP2013/052485 WO2014121840A1 (en) 2013-02-07 2013-02-07 Induced dendritic cells and uses thereof
PCT/EP2014/051422 WO2014122035A2 (en) 2013-02-07 2014-01-24 Induced dendritic cells and uses thereof

Publications (2)

Publication Number Publication Date
CA2899786A1 CA2899786A1 (en) 2014-08-14
CA2899786C true CA2899786C (en) 2023-03-07

Family

ID=47664310

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2899786A Active CA2899786C (en) 2013-02-07 2014-01-24 Induced dendritic cells and uses thereof

Country Status (5)

Country Link
US (2) US10272111B2 (enExample)
JP (1) JP6866988B2 (enExample)
CN (1) CN105025924A (enExample)
CA (1) CA2899786C (enExample)
WO (2) WO2014121840A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105039256A (zh) * 2015-07-13 2015-11-11 中政道和（北京）生物科技有限公司 一种支气管镜下获取肿瘤组织进行树突细胞培养扩增方法
JP7019578B2 (ja) 2015-12-30 2022-02-15 セルジーン コーポレイション Ｔリンパ球の産生方法及びそれにより産生されるｔリンパ球
KR102646596B1 (ko) * 2016-12-21 2024-03-13 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 입양 세포 요법에서 t 세포 활성화를 매개하는 ccr2+ 조혈 줄기 세포
EP3622056A1 (en) * 2017-05-10 2020-03-18 Aarhus Universitet Interferon primed plasmacytoid dendritic cells
WO2019040655A1 (en) * 2017-08-22 2019-02-28 The Regents Of The University Of California LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES
CA3106403A1 (en) 2018-07-15 2020-01-23 Enochian BioPharma, Inc. Methods and compositions using recombinant dendritic cells for cancer therapy
WO2021046243A2 (en) 2019-09-03 2021-03-11 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
MX2022007107A (es) * 2019-12-11 2022-11-14 Myeloid Therapeutics Inc Composiciones celulares terapeuticas y metodos de preparacion y usos de las mismas.
US10980836B1 (en) * 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
KR20230042671A (ko) * 2020-05-28 2023-03-29 바이오마그네틱 솔루션스 엘엘씨 단일 항체를 이용한 나이브 t 및 b 세포의 음성 선택을 위한 조성물 및 방법
CN111647563A (zh) * 2020-08-06 2020-09-11 北京翊博普惠生物科技发展有限公司 靶向Survivin全抗原的DC细胞、CTL细胞及其制备方法和应用
WO2022108306A1 (ko) * 2020-11-17 2022-05-27 성균관대학교산학협력단 인터류킨-33을 처리하여 면역원성이 향상된 cd103+ fcgr3+ 수지상세포의 제조방법 및 상기 수지상세포를 포함하는 면역항암치료용 약학적 조성물
KR20240013094A (ko) 2021-03-17 2024-01-30 마이얼로이드 테라퓨틱스, 인크. 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법
WO2022241029A1 (en) 2021-05-11 2022-11-17 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
CN113881631B (zh) * 2021-10-11 2022-08-02 北京翊博普惠生物科技发展有限公司 一种扁桃体来源的Tγδ细胞及其制备方法和应用
CN117625531A (zh) * 2022-08-30 2024-03-01 浙江吉量科技有限公司 树突细胞祖细胞的制备方法及其培养基

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201403703XA (en) * 2009-06-29 2014-10-30 Qingfeng Chen Methods of producing humanized non-human mammals
DE102012207453B4 (de) 2012-05-04 2017-10-19 Technische Universität Dresden Humanisierte Mäuse ohne Konditionierung

Also Published As

Publication number Publication date
US10272111B2 (en) 2019-04-30
CA2899786A1 (en) 2014-08-14
US20160038541A1 (en) 2016-02-11
JP2016513953A (ja) 2016-05-19
JP6866988B2 (ja) 2021-04-28
US11413307B2 (en) 2022-08-16
US20190247430A1 (en) 2019-08-15
WO2014121840A1 (en) 2014-08-14
WO2014122035A9 (en) 2014-12-11
WO2014122035A3 (en) 2014-10-23
WO2014122035A2 (en) 2014-08-14
CN105025924A (zh) 2015-11-04

Similar Documents

Publication Publication Date Title
US11413307B2 (en) Induced dendritic cells and uses thereof
JP7351533B2 (ja) 改変キメラ抗原受容体（ｃａｒ）ｔ細胞のヒト応用
Juno et al. Cytotoxic CD4 T cells—friend or foe during viral infection?
US9885021B2 (en) Generation of broadly-specific, virus-immune cells targeting multiple HIV antigens for preventive and therapeutic use
ES2907581T3 (es) Método mejorado para la generación de células genéticamente modificadas
JP6516740B2 (ja) 幹細胞及びキメラ抗原受容体を介した抗腫瘍性ｔ細胞免疫の改変
ES3057086T3 (en) Car for use in the treatment of hvg disease
US20140057354A1 (en) Antigen-specific regulatory t-cell induction
JPWO2012020757A1 (ja) 細胞集団の製造方法
Daenthanasanmak et al. Engineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMV
US20230210902A1 (en) Sars-cov-2-specific t cells
Daenthanasanmak et al. Integrase-defective lentiviral vectors encoding cytokines induce differentiation of human dendritic cells and stimulate multivalent immune responses in vitro and in vivo
Thomas et al. Strong and sustained effector function of memory‐versus naïve‐derived T cells upon T‐cell receptor RNA transfer: Implications for cellular therapy
EP2953644B1 (en) Induced dendritic cells and uses thereof
Ha et al. Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity
Ramírez et al. Impact of T cell selection methods in the success of clinical adoptive immunotherapy
Salguero et al. Preconditioning therapy with lentiviral vector-programmed dendritic cells accelerates the homeostatic expansion of antigen-reactive human T cells in NOD. Rag1−/−. IL-2rγc−/− mice
Gao T and B cell collaboration in response to vaccination
RU2779844C2 (ru) Вето-клетки, полученные из т-клеток памяти
Nagy Acceptance of allogeneic cell transplants without systemic immune suppression
Panchal Developing novel therapies for X-linked lymphoproliferative disease type 1
Memory Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination?
Naranjo-Gomez et al. Immunomodulatory Role of NK Cells during Antiviral Antibody Therapy. Vaccines 2021, 9, 137
Macke et al. Dendritic Cell
Chow Improving Hematopoietic Stem Cell Transplantation by Developing New Tools to Reduce Donor Cell Rejection

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181003

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250724

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106